LAGUNA NIGUEL, Calif.--(BUSINESS WIRE)--Aeolus Pharmaceuticals, Inc. (OTCBB:AOLS) announced today that it has secured patent protection via the European Patent Office for its patents disclosing and claiming its lead clinical compound, AEOL 10150, and its Pipeline compounds, including AEOL 11207. Having passed the required European patent opposition period unopposed, the European patents that claim AEOL 10150 (pending through January 25, 2020) and AEOL 11207 and other members of the Pipeline series (pending through April 23, 2019) are now claimed in issued patents in the following European countries: Germany, Denmark, Spain, France, the United Kingdom, Ireland, Italy and Sweden.
